IMIDAZODIAZEPINE COMPOUND - ASTELLAS PHARMA INC

Title:

IMIDAZODIAZEPINE COMPOUND

Document Type and Number:

WIPO Patent Application WO/2016/204268

Kind Code:

A1

Abstract:

[Problem] To provide a compound useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM). [Solution] The present inventors have studied on compounds each of which has a positive allosteric modulating activity (a PAM activity) on a dopamine D1 receptor and can be used as an active ingredient for a prophylactic or therapeutic pharmaceutical composition for cognitive dysfunction, schizophrenia negative symptoms, CIAS, Parkinson's disease, Alzheimer's disease, Huntington's disease, depression, ADHD, drug dependence and the like. As a result, it is confirmed that an imidazodiazepine compound according to the present invention has a PAM activity on a dopamine D1 receptor, and the present invention has been accomplished. The imidazodiazepine compound according to the present invention has a PAM activity on a dopamine D1 receptor and is expected to be used as a prophylactic and/or therapeutic agent for cognitive dysfunction, schizophrenia negative symptoms, CIAS, Parkinson's disease, Alzheimer's disease, Huntington's disease, depression, ADHD, drug dependence and the like.

Inventors:

KAWAKAMI SHIMPEI (JP)
IMAIZUMI TOMOYOSHI (JP)
MASUDA NAOYUKI (JP)
KUNIKAWA SHIGEKI (JP)
MORITA MASATAKA (JP)
YARIMIZU JUNKO (JP)

Application Number:

PCT/JP2016/068080

Publication Date:

December 22, 2016

Filing Date:

June 17, 2016

Export Citation:

Click for automatic bibliography generation Help

Assignee:

ASTELLAS PHARMA INC (JP)

International Classes:

C07D487/04; A61K31/551; A61P25/14; A61P25/16; A61P25/18; A61P25/28; A61P25/36; A61P43/00

Domestic Patent References:

WO2014171528A1	2014-10-23
WO2004000837A1	2003-12-31
WO2011163355A1	2011-12-29
WO2005080334A1	2005-09-01
WO2005118561A1	2005-12-15

Other References: